Issue of Equity

Iconic Labs PLC
02 June 2023
 

Iconic Labs PLC

 

("Iconic" or the "Company")

 

EHGOSF Subscribes for a £180,000 Sixth Tranche Under £3 million Financing Facility

 and Conversion of Notes

Iconic Labs PLC (LSE: ICON) announces that the European High Growth Opportunities Securitization Fund ("EHGOSF") has subscribed for a £180,000 sixth tranche of convertible notes under the £3 million financing facility (the "Facility") that was entered into on 28 September 2022. This subscription takes the total subscribed under the Facility to £1,030,000.

In exchange, Iconic will issue 180 convertible notes to EHGOSF along with 3,000,000,000 warrants with an exercise price of £0.00003.

The funds under this sixth tranche will be used to meet Iconic's obligations under the CVA, for operational purposes, and preparation of  an FCA approved prospectus which will enable Iconic to issue further Ordinary Shares pursuant to its obligations to unsecured creditors under the CVA, EHGSOF under the Facility, various parties under the settlement deeds, and management for outstanding fees. 

In addition, Iconic announces that it has received a valid conversion notice from the EHGSOF ("Conversion Notice")..

 

The Conversion Notice was dated 1 June 2023 and provides for 30 Convertible Notes to be converted into 1,200,000,000 ordinary shares of £0.00001 ("Ordinary Shares") in the Company at a conversion price of £0.000025 at the aggregate principal amount of £30,000.

Application is being made for the 1,200,000,000 new Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange which is expected to be on or around 8 June 2023. These shares rank pari passu with the existing Ordinary Shares of the Company.

Following the issue of these shares, the Company's issued ordinary share capital shall consist of 46,306,916,660 Ordinary Shares. The figure of 46,306,916,660 represents the total voting rights in the Company and should be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance & Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

For any further information or enquiries please contact:

 

ir@iconiclabs.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Iconic Labs (ICON)
UK 100

Latest directors dealings